>Improving sales momentum is partially offset by SG&A inflation - Total Q3 revenues reached € 119m (+9% y-o-y vs 9% sales growth registered in Q2), a touch ahead of our estimate and the consensus. By division, sales of traditional products in Spain posted some sequential improvement (10% y-o-y in Q3 2024 vs 4% in Q2 and 14% in Q1), reflecting the positive impact that new formats are having in Bilastine that are offsetting the price reductions (+11% in Q3 vs -2% in Q2 ...
>Sales lose momentum in Iberia and Animal health but the Exports save the quarter - Total Q2 revenues reached € 134m (+9% y-o-y vs 7% sales growth registered in Q1), a touch ahead of our estimate. By division, sales of traditional products in Spain posted some sequential deterioration (4% y-o-y in Q2 2024 vs 14% in Q1), reflecting a softening of momentum in Bilastine (-2% in Q2 vs +5% in Q1) and flattish Mesalazine which were partially offset by a good evolution of Ca...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.